Inhibition of Escherichia coli DNA polymerase-I by the anti-cancer drug cis-diaminedichloroplatinum(II): what roles do polymerases play in cis-platin-induced cytotoxicity?  by Duman, Rebecca K. et al.
Inhibition of Escherichia coli DNA polymerase-I by the anti-cancer drug
cis-diaminedichloroplatinum(II): what roles do polymerases play in
cis-platin-induced cytotoxicity?
Rebecca K. Dumana, Robert T. Heathb, Rathindra N. Bosea;*
a Department of Chemistry, Kent State University, Kent, OH 44242, USA
b Department of Biological Sciences, Kent State University, Kent, OH 44242, USA
Received 5 April 1999; received in revised form 2 June 1999
Abstract Activities of Escherichia coli DNA polymerase-I were
examined in the presence of the anti-tumor drug cis-diaminedi-
chloroplatinum(II) and its inactive geometric isomer trans-
diaminedichloroplatinum(II). The trans-isomer did not inhibit
the enzyme activity. The anti-tumor drug, on the other hand,
retarded the enzyme in its ability to extend the primer strand of
DNA. Two alternative mechanisms of inhibition, covalent
binding of cis-diaminedichloroplatinum(II) to the polymerase
and to the template DNA, were explored. Selective pre-
incubations of the platinum drug with the polymerase and
DNA reveal that the inhibition is primarily due to covalent
binding to the enzyme. The rates of inhibition were found to be
first order in enzyme and zeroth order in platinum in the
concentration range 0.05^3.0 mM. A mechanism that deals with
the formation of an initial platinum^polymerase-I complex with
a binding constant s 105 M31 followed by a further reaction to
form an inhibitory complex is consistent with the kinetic data.
The rate limiting first order rate constant for the formation of the
inhibitory complex is comparable to that observed for the thiol
coordination of peptides containing cysteine residues. Analyses of
known structures and functions of catalytic domains of various
polymerases point to the direction that the inhibition is perhaps
due to the distortion of the DNA binding domain of the enzyme
due to platinum coordination.
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1. Introduction
cis-Diamminedichloroplatinum(II) (cis-DDP) is a widely
used anti-cancer drug [1,2]. The platinum compound arrests
cell synthesis in the G2 phase of the cell cycle by a mechanism
commonly known as apoptosis [3^6]. At the molecular level,
platinum-DNA adducts are believed to be the lesions respon-
sible for anti-cancer activity [7^9]. However, how the plati-
nated DNA lesions lead to apoptosis is yet to be elucidated.
Although both in vitro and in vivo experiments clearly indi-
cate platinum binding to DNA, a signi¢cant amount of this
metal also binds proteins [10]. Unfortunately, studies related
to platinum binding to proteins have mainly addressed issues
related to toxicities of the drug [11,12]. The implications of
direct covalent binding to replication enzymes which are in-
volved in cell synthesis have not been explored in detail. In
order to gain a comprehensive understanding of the anti-can-
cer mechanism, it is desirable to investigate all molecular
events that might lead to apoptosis. Since platinum(II) exhib-
its a tremendous a⁄nity toward sulfur donor atoms [13^18],
such as cysteine and methionine in proteins, over the nitrogen
donor sites in DNA, reactions with enzymes rich in cysteine
and methionine cannot be ignored. One such enzyme is the
DNA polymerase-K that contains many cysteine residues in
the DNA binding domain of the enzyme [19]. This key repli-
cation enzyme is solely responsible for accurate synthesis of
genetic information [20]. Recently, we have shown that cis-
DDP can directly bind to the enzyme and inhibit its activity
[21]. Also, it has been demonstrated that DNA polymerase-L,
a repair enzyme, can bypass the platinated DNA lesions in
carrying out the chain extension reaction implying that plati-
nated DNA can still be used as a template for DNA synthesis
[22]. Furthermore, a very small fraction (V1%) of the admin-
istered cis-DDP reaches genomic DNA and the rest of the
drug binds proteins, RNA, small thiols and thioether includ-
ing glutathione, cysteine and methionine [15]. We have under-
taken a systematic study to examine the role of replication
enzymes toward the anti-cancer mechanism of platinum
anti-tumor drugs. Here, we present results related to the in-
hibition of Escherichia coli DNA polymerase-I by cis-DDP
and compare those with trans-DDP, the inactive isomer. Since
E. coli polymerase-I is both structurally and functionally well-
characterized [23^25] and its functions are comparable to
those of human DNA polymerases, studies related to the in-
teractions between cis-DDP and E. coli pol-I might o¡er in-
sight into the binding sites of the platinum complex that lead
to inhibition of the enzyme activities.
2. Materials and methods
2.1. Reagents
cis-DDP was synthesized by the method of Dhara [26]. E. coli DNA
polymerase-I (pol-I) (EC 2.7.7.7, catalog number D9380) with an
activity of 10 U/Wl was purchased from Sigma. The highest available
purity of all 2P-deoxy nucleoside-5P-triphosphates (dNTPs, 2P-deoxy
adenosine-5P-triphosphate, 2P-deoxy cytosine-5P-triphosphate, thymi-
dine-5P-triphosphate and 2P-deoxy guanosine-5P-triphosphate) was
also purchased from Sigma. Methyl [3H]thymidine-5P-triphosphate
with a speci¢c activity of 15 Ci/mmol was purchased from ICN Phar-
maceuticals. Double-stranded calf thymus DNA (type XV) was acti-
vated by the method of Aposhian and Kornberg [27] by using deox-
yribonuclease-I. A xylene-based scintillation cocktail was purchased
from Fischer Scienti¢c. Serum albumin, dithiothreitol (DTT) and
L-cysteine (Sigma) were used without further puri¢cation. All other
common reagents such as MgCl2, KCl and EDTA were used without
further puri¢cation. Bu¡ers such as phosphate and Tris were prepared
from appropriate acids and their conjugate bases.
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2.2. Physical measurements
2.2.1. Liquid scintillation counting. Tritiated material was spotted
on a weakly basic anion exchange paper (Fischer Scienti¢c DE-81),
dried thoroughly in a microwave oven, then placed in liquid scintilla-
tion vials containing 10 ml of scintillene cocktail (Fischer Scienti¢c).
Radioactivity was determined in a Beckman LS 6800 liquid scintilla-
tion counter with quench detection (137Cs external standard to give
the H number) and micro-processed automatic quench correction.
The unquenched tritium counting e⁄ciency was 0.61. A quench cor-
rection curve was determined from a set of quenched tritium stand-
ards (Beckman). Using this quench correction curve and the detected
quenching of each sample, we calculated the 3H desintegrations per
minute (dpm) directly from the background corrected 3H counts per
minute (cpm).
2.2.2. Ultraviolet-visible (UV-vis) measurements. Rates of reac-
tions between cis-DDP and DTT were measured on a computer-in-
terfaced UV-Visible spectrophotometer (Perkin Elmer Lambda 600)
by following the change in absorbance at 260 nm as a function of the
time. The temperature was maintained constant at 37‡C and the ionic
strength was maintained at 0.5 M by NaClO4. The reactions were
carried out by using at least a 10-fold excess of the ligand over the
platinum complex.
2.2.3. High performance liquid chromatographic (HPLC) separa-
tions. Reactants, intermediates and products of the reaction between
cis-DDP and DTT were separated on a Gradient HPLC system
(Waters 7400) by using a reversed phase C-18 column with a mobile
phase, 50 mM Tris bu¡er (pH = 6.8).
2.2.4. Activity assay of E. coli DNA polymerase-I. The activity of
pol-I was determined by the amount of [3H]TMP incorporation into a
nicked and gapped calf thymus DNA [28]. The following components
were present in a typical assay mixture of a total volume of 100 Wl :
400 Wg/ml calf thymus DNA, 50 mM Tris bu¡er (pH = 7.4), 5 mM
MgCl2, 20 mM KCl, 5 mM DTT, 50 Wg bovine serum albumin, 50 WM
each of dATP, dCTP, and dGTP, 50 WM [3H]TTP and 6 U pol-I. The
assay mixture was incubated in a thermostat at 37‡C for 45 min. The
reaction was stopped by adding 50 Wg of serum albumin and ice cold
10% trichloroacetic acid containing 100 mM pyrophosphate. The so-
lution was vortexed brie£y at a low speed and then placed on a rock
salt ice water bath for 45 min to complete the precipitation. The
precipitate was collected on an ion exchange paper and washed with
15 ml ice cold trichloroacetic acid containing 50 mM sodium pyro-
phosphate. The precipitate was further washed with 5 ml water, etha-
nol and then with acetone. The paper was then soaked in a large Petri
dish containing 3 M sodium phosphate to remove any unincorporated
dNTPs from the ion exchange paper. Following the removal of un-
reacted substrates, the paper was placed into a microwave oven for
1 min. Once dried, it was then placed into a 20 ml glass scintillation
vial combined with 10 ml scintillation £uid. The radioactivity was
then counted on a scintillation counter and 3H cpm were converted
to 3H dpm.
2.2.5. Activity assay in the presence of platinum complexes. The
activities of the enzyme in the presence of cis- and trans-DDP were
measured in several di¡erent ways. In one approach, platinum com-
pounds were incubated along with the assay mixture for a speci¢ed
amount of time. These complexes were then deactivated by adding
cysteine which reacts fairly rapidly (in minutes) with the platinum(II)
center [13^15]. Additions of cysteine did not alter the activity as dem-
onstrated by appropriate controls. In the second method, the plati-
num compounds were incubated with the enzyme for the desired
length of time. The unreacted platinum was then deactivated by add-
ing cysteine. The platinated enzyme was then added to the assay
mixture described earlier and the activity was measured. Finally, in
the third method, activated DNA was incubated ¢rst with platinum
compounds for variable times and unreacted platinum was once again
removed by cysteine. The platinated DNA was then added to the
assay mixture. The same assay protocol was then followed to measure
the activity.
2.2.6. Evaluation of rate constants. For a given platinum concen-
tration, the activity of the enzyme was monitored at regular time
intervals. The activity-time curves can be described by an exponential
decay. These curves were then ¢tted to the equation:
Ac  Aco3Acre3kt  Acr 1
by a non-linear least-squares method utilizing an iterative computer
program. In this equation, Aco, Ac and Acr are the activity at time
t = 0, at t and at in¢nite time when no appreciable changes in the
activity were observed. The experimental data were found to be in a
good ¢t with the calculated data.
The rate constants for the reaction between cis-DDP and DTT were
evaluated from the absorbance time curves. These kinetics can be
described best by a biphasic pro¢le following a consecutive reaction
sequence:
cis-DDPDTTÿ!k1 intÿ!k2 products 2
where int represents an intermediate in the reaction. Following the
above reaction sequence, it can be shown that the absorbance as a
function of time can be described by [29]:




k1e3k2t3k2e3k1t  Ar 3
A non-linear least-squares ¢t of the kinetic data yielded values for the
two rate constants and the molar absorption of the intermediate. The
values of Ao (initial absorbance), Ar (absorbance at in¢nite time) and
[DDP]o (initial concentration of the platinum complex) were kept
invariant. In triplicate measurements, the deviation of the rate con-
stants from their mean values was within 10%.
3. Results
3.1. Inhibition of polymerase activities by cis-DDP
The activity of DNA polymerase-I was measured by mon-
itoring the incorporation of [3H]TMP in a nicked and gapped
calf thymus DNA. Fig. 1 shows a typical activity-time curve.
The maximum activity was reached after 60 min of incubation
of the enzyme with the substrates. Identical experiments were
performed in the presence of 1.0 and 3.0 mM cis-DDP. These
activity-time curves are also displayed in Fig. 1. Although
maximum activities were achieved after 30 min, these activities
were substantially lower than those observed in the absence of
cis-DDP. The inhibition thus observed appears to be irrever-
sible, since no enhancement of the activity was observed even
with a prolonged incubation. This irreversible inhibition may
be due to covalent binding of cis-DDP with either DNA or
the polymerase. In order to address the origin of this irrever-
sible inhibition, cis-DDP was incubated selectively with pol-I
and DNA and then, the activities were measured. Further-
more, identical experiments were also carried out with the
inactive trans-isomer.
3.2. DNA polymerase-I activity from cis-DDP bound enzyme
cis-DDP was incubated with pol-I for various times. Fol-
lowing incubation, the activity of the enzyme was assayed by
Fig. 1. Activity-time pro¢les for E. coli polymerase-I in the absence
(F) and presence (R) of 1.0 (A) and 3.0 (B) mM cis-DDP.
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[3H]TMP incorporation. The activity-time curves at several
platinum concentrations are shown in Fig. 2. The activity at
time t = 0 min corresponds to the activity of the enzyme in
controls. As can be seen from the diagram, at a given con-
centration, the activity ¢rst decreases with an increasing incu-
bation time and then ¢nally levels o¡ at longer times. In
particular after 120 min, insigni¢cant changes in the activity
were observed for the platinum concentrations employed here,
0.05^3.0 mM. These data clearly indicate that cis-DDP is an
inhibitor of pol-I.
The activity-time curves can be described by a ¢rst order
rate pro¢le. The rate constants obtained from the non-linear
least-squares ¢t of the ¢rst order equation are listed in Table
1. The data indicate that there is no signi¢cant variation of
the rate constant with [cis-DDP], indicating that the inhibition
is zeroth order with respect to platinum under the experimen-
tal conditions. The kinetic data can be explained by a mech-
anism:
cis-DDP pol-IHK cis-DDP; pol-I 4
cis-DDP; pol-Iÿ!k cis-DDPÿpol-I 5
cis-DDPÿpol-IDNANTPs! no reaction 6
According to this mechanism, the observed rate constant k0
can be related to:
k0  kK cis-DDPpol-I1 K cis-DDP 7
Since the observed rate constant was invariant in platinum
concentrations, K[cis-DDP]s 1, the lower limit of K can be
set to 105 M31.
cis-DDP also undergoes a parallel reaction with DTT. As
can be seen from Table 1, at lower platinum concentrations
(6 500 WM), complete retardation was not observed primarily
due to the depletion of platinum complex by a parallel reac-
tion with DTT. In order to estimate the amount of platinum
available for the enzymatic reaction, kinetics of the cis-DDP^
DTT reaction were examined under identical conditions. The
reaction between cis-DDP and DTT follows consecutive ki-
netics with the formation and decay of a cis-DDP^DTT in-
termediate. The formation of the intermediate follows the
well-established two-term rate law with the rate constants
for the aquation (ko), (1.2 þ 0.1)U1034 s31 and for the direct
reaction (k), (1.0 þ 0.1)U1032 M31 s31. The formation of the
product was found to be a ¢rst order process with respect to
the intermediate with a rate constant of (2.3 þ 0.2)U1034 s31.
The sequence of reactions is shown by Eqs. 8^10:




cis-PtNH32ClÿDTTintÿ!k2 cis-PtNH32DTT  Cl3
10
In the intermediate, one of the two available thiol groups of
DTT is bound to the platinum center. However, we have
detected two products in the HPLC chromatograms. The
products are most likely to be a bis-(DDT) complex in which
two molecules of DTT are bound to the platinum center in a
monodentate fashion and a DTT chelate in which both thiol
groups of the molecule are coordinated. The ¢rst order ki-
netics and magnitude of k2 support that the formation of
the products is mainly limited by the rate of aquation [30^
32]. Since our objective was to evaluate the fraction of plati-
num bound to this reducing agent, we did not attempt to fully
characterize these DTT complexes. The concentration pro¢les
for the cis-DDP, the intermediate and products for a typical
reaction are shown in Fig. 3.
As indicated earlier, zeroth order kinetics of pol-I inhibition
with respect to platinum requires a binding constant, s 105
M31, for an inhibitory enzyme-platinum complex. An inde-
pendent estimate of the binding constant can also be obtained
from the activity data with the consideration that the meas-
ured activities at time s 90 min, i.e. when no further changes
were observed, were due to establishment of an equilibrium.
Fig. 2. Inhibitions of E. coli polymerase-I activity due to cis-DDP
pre-incubations with the enzyme. Concentrations of cis-DDP were
A, 0.050 mM, B, 0.4 mM and C, 3.0 mM. Solid lines are simulated
pro¢les using Eq. 1 with the rate constants listed in Table 1.
Table 1
First order rate constants for E. coli polymerase-I inhibition as a
function of [cis-DDP] at 37‡C and at pH 7.0
[cis-DDP]o, M [cis-DDP]eq, M ko, s31 Activityeq, dpm
5.0U1035 1.4U1035 1.0U1033 1.36U104
1.0U1034 2.7U1035 8.9U1034 1.25U104
4.0U1034 1.1U1034 8.0U1034 9.29U103
3.0U1033 8.2U1034 1.1U1033 1.64U103
zThe equilibrium concentrations of cis-DDP and the polymerase ac-
tivity in dpm are also listed
Fig. 3. Concentration pro¢les of cis-DDP (A), cis-DDP^DTT inter-
mediate (B) and products (C) for the reaction of cis-DDP (1.0 mm)
and DTT (5.0 mM) at pH 7.0, determined based on the kinetic
scheme I by utilizing the rate constants indicated in the text.
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Table 1 also lists the activity of the enzyme as a function of
cis-DDP concentrations at 120 min which can be used to
evaluate the binding constant as described below. The binding
constant, K, for the reaction:
cis-DDP pol-IHK cis-DDPÿpol-I 11
can be expressed as:
K  Eo3EEPto3Eo  E3PtÿDTT 12
where [Pt]o and [E]o are the initial concentrations of the plat-
inum complex and enzyme and [E] and [Pt^DTT] are the
concentrations of the enzyme and platinum^DTT complexes
at equilibrium. Since both [E]o and [E] are several orders of
magnitude smaller than [Pt]o and the activity of enzyme is
proportional to its concentration, the binding constant can
be expressed as:
K  Aco3AcAcPto3PtÿDTT 13
where (Ac)o and (Ac) correspond to the activities of the en-
zyme of the control experiment (without platinum) and in the
presence of platinum when equilibrium was achieved. A plot
of [Pt]ef ([Pt]o3[Pt^DTT]) versus (Ac)31 yielded a binding con-
stant of (5 þ 2)U104 M31. This value of the binding constant
must be a lower limit since at physiological pH of cis-DDP is
also known to form hydroxo-bridged dimers and trimers
[33,34] and other complexes through parallel reactions and
accurate estimates of concentrations of these species are di⁄-
cult to achieve.
3.3. DNA polymerase-I activity in the presence of trans-DDP
The polymerase activities were also determined in the pres-
ence of trans-DDP, the inactive isomer. The same experimen-
tal protocol as described for the cis-DDP counterpart was
followed, i.e. the polymerase activities were measured follow-
ing selective pre-incubation of trans-DDP with the polymer-
ase. Fig. 4 shows the activity time data for the highest plati-
num(II) concentration, 3.0 mM. As can be seen from the plot,
even at this high platinum concentration, there is no signi¢-
cant inhibition of the enzyme. There is, however, considerable
scattering of the activity data compared to those obtained for
the cis-DDP reactions. This scattering appears not to be en-
tirely related to experimental uncertainty or artifacts because
of its reproducibility.
3.4. Inhibition of DNA polymerase-I activity due to cis- and
trans-platination to DNA
In order to understand the role of platinated DNA toward
polymerase inhibition, cis- and trans-DDP were individually
incubated with the nicked and gapped DNA. The enzyme
activities were measured by deactivating the unreacted plati-
num complexes with cysteine. Fig. 4 shows the activity-time
curves for cis- and trans-DDP reactions. Unlike the cis-DDP^
polymerase pre-incubation experiments, at times up to 30 min,
the incubation of cis-DDP with DNA did not result in any
signi¢cant inhibition. In fact, activity-time curves obtained by
pre-incubations with DNA appeared to be indistinguishable
from those obtained for the control experiments. However, at
longer times, some inhibition was apparent for the DNA pre-
incubations. After 120 min, less than 10% inhibition was ob-
served. Likewise, trans-DDP^DNA incubations did not result
in any signi¢cant inhibition of the enzyme.
4. Discussion
Results presented in the previous section unequivocally es-
tablish that cis-DDP but not the trans-isomer inhibits the
activity of DNA polymerase-I as observed by the nick and
gap translation assay. Furthermore, the lowest cis-DDP con-
centration used in this study is comparable to doses adminis-
tered to patients [1]. The inhibition mechanism appears to be
irreversible. Comparative experiments dealing with DNA ver-
sus polymerase pre-incubations clearly point primarily to en-
zyme binding events responsible for the inhibition. The rate of
inhibition should correspond to the rate of substitutions onto
platinum(II) if the irreversible complex formation between
DNA or polymerase was the event responsible for the lack
of enzyme activity. The postulated mechanism requires the
formation of an initial complex for which only a binding
constant s 105 M31 can be estimated but not the rate con-
stant. This initial complex then undergoes further reaction
(rearrangements) to form a product, presumably an inhibitory
complex by a ¢rst order process. However, the ¢rst order rate
constant, (1.0 þ 0.1)U1033 s31, is comparable to what we
measured for a chelation step for a peptide with two cysteine
residues. Furthermore, this rate constant is about two orders
of magnitude larger than that of aquation of cis-DDP, the
process that limits DNA coordination.
In order to inhibit polymerase-I activities, cis-DDP can ei-
ther directly bind to the active sites of the enzyme [38^42],
modify the substrates which are not recognized by the en-
zyme, or cause structural changes elsewhere in the enzyme
such that it does not recognize substrates or template DNA.
The possibility that the modi¢ed substrates, due to direct
platinum binding to dNTPs, are the source of inhibition can
be ruled out. The reactions of dNTPs and dNMPs with the
platinum(II) complex are much slower compared to those
observed here [35^37]. Furthermore, if modi¢ed substrates
are the source of inhibition, similar activities were expected
for the enzyme regardless of the polymerase or DNA pre-
incubations. The inhibition was observed when pol-I was
pre-incubated with cis-DDP or both DNA and pol-I are co-
incubated with the platinum complex. Moreover, we did not
observe the inhibition for the trans-DDP system, yet the re-
Fig. 4. Activity-time plots for E. coli polymerase-I due to pre-incu-
bation of cis-DDP with DNA (F) and trans-DDP with DNA (a)
and the polymerase (b). Note that none of these pre-incubations re-
sults in signi¢cant inhibitions.
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actions of the trans-isomer are generally faster than that of the
cis-counterpart. Platinum(II) binding at the polymerization
active site and dNTP binding sites can also be argued against.
The absence of potential coordination sites in these amino
acids except histidine makes it di⁄cult to bind cis-DDP.
Although histidine has a potential nitrogen donor site, its
reaction with the platinum complex is comparable to that of
N7 donor sites of purines but slower than that observed here.
Since reactions between platinum(II) and sulfur donor sites,
especially thiols and thioethers, are shown to be much faster,
it is conceivable that platinations at these residues might also
have led to major structural distortions. In fact, X-ray struc-
tural data reveal that the Klenow fragment of the enzyme
contains a large cleft between the two major helices which
contain several cysteine, methionine and histidine residues.
The template DNA is believed to ¢t snugly in the cleft [23].
Therefore, it is highly likely that structural changes due to
covalent binding to cis-DDP might lead to a lack of DNA
recognition. The structural distortions can also be supported
from our earlier observation that cis-DDP readily replaces
Zn(II) from the DNA binding domain of PA3 polymerase-K
[28]. Furthermore, we have reported the facile formation of
cis-DDP^peptide complexes containing nine and 31 amino
acids from this DNA binding domain of polymerase-K [43]
which undergo severe structural perturbations due to platina-
tion [44,45].
The polymerase inhibition results should be evaluated in the
context of an anti-cancer mechanism of cis-DDP. The anti-
cancer mechanism is commonly believed to be due to the
formation of a variety of platinum^DNA adducts including
DNA^protein cross links. To date, roles of polymerases have
been con¢ned to their inabilities to utilize platinum^DNA
adducts as the template toward DNA synthesis [22,46^48].
However, Harder et al. [46] reported signi¢cant inhibition of
pol-K and -L isolated from RPMI cells with 500 WM cis-DDP,
but at lower platinum concentrations, marginal inhibitions
were observed. It is not clear whether the lack of substantial
inhibitions was due to limited exposure of the drug to the
enzyme, a substantial loss of cis-DDP through dimerization
and rapid reaction of pre-equilibrated cis-DDP with DTT, the
nature of the enzymes or di⁄culty to isolate the enzymes in
their pure forms. Furthermore, Ho¡man and co-workers [22]
reported that polymerase-L recognized the platinated DNA
template in contrast to observations reported by Harder
[46]. Moreover, we have reported [21] polymerase-K inhibi-
tions by both cis-DDP and dichloro(ethylenediamine)plati-
num(II). Certainly, more studies are needed to address the
issues pertaining to the diversities of polymerase activities iso-
lated from a variety of cells and organisms and comparison of
the rates of inhibitions due to DNA versus polymerase bind-
ing to platinum drugs.
Although platinum-adducts are believed to be the primary
lesions responsible for the anti-cancer mechanism, other
mechanisms including protein-platinum bindings have yet to
be ruled out. Roles of a variety of repair enzymes and archi-
tectural proteins have been examined in relation to acquired
drug resistance and di¡erential behaviors of cis- and trans-
DDP toward cytotoxicity [49^52]. For example, a number of
structure speci¢c recognition proteins block the repair of cis-
DDP-mediated DNA damage caused mainly by an intra-
strand 1,2-binding mode to adjacent G or G-A, while trans-
platin-DNA adducts are repaired by the same proteins. These
bifunctional cis-DDP^DNA adducts cause severe structural
distortions to DNA [53^56]. Since anti-tumor platinum com-
plexes with one binding site [57] cannot cause such distortions,
a di¡erent mechanism must be invoked. In search for a com-
mon mechanism, we are currently examining the polymerase
inhibition by a variety of platinum complexes that o¡er both
one and two coordination sites [58]. Finally, although the data
presented here did not unambiguously establish a new anti-
cancer mechanism since the fate of cis-DDP in the cellular
milieu cannot be de¢ned to a speci¢c molecular event, they
provided impetus for thorough and systematic investigations
for the roles of platinum-protein adducts toward the cytotox-
icity of platinum drugs. It is interesting to note that polymer-
ase inhibition has led to apoptosis by an antibiotic, aphidico-
lin, and the onset of DNA degradation by both cis-DDP and
the antibiotic appears to be the same [3^5].
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